Skip to main content
. Author manuscript; available in PMC: 2007 Sep 21.
Published in final edited form as: Pharmacogenet Genomics. 2007 Jan;17(1):37–45. doi: 10.1097/01.fpc.0000236325.73186.2c

Figure 5.

Figure 5

Recombinant human NAT2 allozymes expressed in E. coli. NAT2 5I and individual SNPs are shown in top panel (A). NAT2 12D and individual SNPs are shown in bottom panel (B). NAT2-411T and NAT2-341C had catalytic activities significantly lower than NAT2 4 (Ref) (*: p<0.01). Catalytic activities of NAT2 5I, NAT2 12D and NAT2-364A were less than the limit of detection (0.3 nmol/min/mg). Western blots for each NAT2 allozyme are also shown underneath the respective bar graph. Ref: NAT2 4 expressed in E. coli; Mock: E. coli transformed with empty plasmid.